Determination of HER2 gene status by fully automated fluorescence microscopy

Analytical and Quantitative Cytology and Histology

Volumn 33, Issue 4, 2011, Pages 205-210

  Kilpatrick, Michael W ^a   Sheehan, Christine E ^b   Marganski, William A ^a   Tafas, Triantafyllos ^a   Ross, Merrill S ^b   Ross, Jeffrey S ^b  

^a Ikonisys Inc   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Automated; Breast neoplasms; Fluorescence; Genes; HER2; In situ hybridization; Microscopy; Status

Indexed keywords

ANTHRACYCLINE DERIVATIVE; TAXANE DERIVATIVE; TRASTUZUMAB;

ACCURACY; ARTICLE; AUTOMATION; BREAST CANCER; CENTROMERE; CHEMOTHERAPY; CHROMOSOME 17; COST CONTROL; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENCE MICROSCOPY; GENE; GENE AMPLIFICATION; HER2 GENE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; TISSUE SECTION; TREATMENT RESPONSE; VALIDITY;

BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MICROSCOPY, FLUORESCENCE; RECEPTOR, ERBB-2;

EID: 80955166885     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA: The neu oncogene: An erb-Brelated gene encoding a 185,000-Mr tumour antigen. Nature 1984;312:513-516
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712
3. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-368
4. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232: 1644-1646
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
6. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in nodenegative breast carcinomas. J Clin Oncol 1997;15:2894-2904
7. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN: Targeted therapy in breast cancer: The HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-398
8. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R: Prognostic importance of c-erbB-2 expression in breast cancer: International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:1049-1056
9. Piccart M, Lohrisch C, Di Leo A, Larsimont D: The predictive value of HER2 in breast cancer. Oncology (Suppl 2) 2001;61: 73e-82e
10. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51
11. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S: Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials. Oncologist 2008;13:620-630
12. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726
13. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672
14. The Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab following adjuvant chemotherapy in HER2-positive early stage breast cancer (HERA trial): Disease-free and overall survival after 2 year follow-up. J Clin Oncol 24, 2006, presented as a late breaking abstract at the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006
15. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145